JHBP (CY) HOLDINGS LIMITED Inactive Instrument
JHBP (CY) Holdings Limited Share Price Hong Kong S.E.
Equities
6998
KYG6501A1013
Biotechnology & Medical Research
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.59Cr 22.02L 1.72Cr 18Cr | Sales 2023 | - | Capitalization | 54Cr 7.53Cr 59Cr 627.24Cr |
|---|---|---|---|---|---|
| Net income 2022 | -73Cr -10Cr -79Cr -840.41Cr | Net income 2023 | -67Cr -9.32Cr -73Cr -775.94Cr | EV / Sales 2022 | -24.3 x |
| Net cash position 2022 | 156.01Cr 22Cr 168.19Cr 1.8TCr | Net cash position 2023 | 115.83Cr 16Cr 124.87Cr 1.33TCr | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.62
x | P/E ratio 2023 |
-0.81
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 66.07% |
More Fundamentals
* Assessed data
More news
Genor Biopharma Holdings Ltd, formerly JHBP CY Holdings Ltd, is China-based company mainly engaged in the research and development of biopharmaceutical products. The Company focuses on the development and commercialization of oncology and autoimmune drugs. The Company's main drugs include lerociclib (GB491), coprelotamab (GB221), geptanolimab (GB226), GB492, GB242 and GB223. The Company mainly conducts its businesses in the China market.
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +9.58% | 12TCr | |
| +12.41% | 11TCr | |
| -2.59% | 2.16TCr | |
| -12.38% | 2.23TCr | |
| -5.29% | 1.92TCr | |
| -3.35% | 1.82TCr | |
| -38.57% | 1.76TCr | |
| +7.51% | 1.43TCr | |
| +35.67% | 1.24TCr |
